Anderson Lisa M sold $92K of IEX

Anderson Lisa M (SVP, GC, CAO & Corp Sec) sold 385 shares of IDEX CORP /DE/ (IEX) at $238.59 on 2026-08-12.

Original reporting
SEC EDGAR · Anderson Lisa M
Published Aug 13, 2026, 10:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 10:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IEX
Neutral
medium confidence
Mentioned
$IEX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IEXNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and post-transaction holdings; it does not include any company performance or forward-looking guidance.

02

Market read

Traders may note the insider sale, but it is typically low-signal absent corroborating fundamental or regulatory news.

03

What to watch

The article provides no context on total holdings, diversification needs, or whether other insiders sold/bought around the same time.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-13, sale dated 2026-08-12

Background

The article is an SEC Form 4 insider transaction disclosure for IDEX Corp (IEX).

Company-level read

Ticker impact

$IEXNeutralMedium confidence
Context

SEC Form 4 shows IDEX Corp officer Anderson Lisa M sold 385 shares at $238.5949 on 2026-08-12, totaling $91,859.04.

Expected impact

Likely minimal near-term impact; treat as low-signal unless repeated or paired with other disclosures.

Evidence & confidence

The filing is primary-source but describes a relatively small, single-tranche sale by an officer, not a company action, guidance change, or material transaction.

Market effects

No clear sector read-through from a single insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales without a disclosed 10b5-1 plan can sometimes reflect liquidity needs or risk management rather than bearish fundamentals, so the signal may be overstated.

Key entities

  • IEX

    IDEX Corp, issuer of the Form 4 insider transaction disclosed in the article.

  • Anderson Lisa M

    SVP, GC, CAO & Corp Sec who reported an open-market sale of 385 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IEXHighAI 8/10

DA Davidson raises IDEX stock price target to $245 on strength

DA Davidson raised its price target on IDEX Corp (NYSE:IEX) to $245 from $240, citing strength in its Health & Science Technologies and Fire & Safety segments. The stock has risen 39% over the past year. IDEX reported Q3 2026 earnings of $2.33 per share, beating estimates, with revenue of $952 million. The company also raised its full-year guidance.

$IEXMedAI 8/10

Idex: Q3 Earnings Snapshot

IDEX Corp. (IEX) reported Q3 net income of $144.1M, or $1.95 per share, exceeding analyst estimates. Adjusted EPS was $2.33. Revenue was $951.7M, also beating forecasts. The company raised its full-year EPS guidance to $8.91-$8.96 per share.

$IEXHighAI 8/10

IDEX (IEX) Q3 2026 Earnings Call Transcript

IDEX (IEX) reported Q3 2026 net sales of $952M, up 8%, and adjusted EPS of $2.33, up 15%. Organic orders reached $991M, growing 13%. HST, FMT, and FSDP segments showed growth. Full-year guidance raised: organic growth 6.5-6.8%, adjusted EPS $8.91-$8.96. Inflation and chemical sector weakness noted as risks.

$IEXHighAI 8/10

IDEX Q3 2026 slides: advantaged markets drive beat, guidance raised

IDEX Corporation (NYSE:IEX) reported Q3 2026 earnings with 8% organic sales growth and 15% increase in adjusted EPS, driven by 'advantaged markets'. Sales reached $952M, adjusted EBITDA margin expanded to 27.8%, and free cash flow grew 14%. The company raised its full-year outlook, with shares up 0.92% to $235.35. HST segment led growth with 13% organic sales growth.

$IEXMedAI 8/10

IDEX (NYSE:IEX) beats Q3 2026 sales expectations

IDEX reported Q3 2026 revenue of $951.7 million, beating estimates by 1.8%. Adjusted EPS was $2.33, a 4% beat. Adjusted EBITDA reached $264.8 million, a 3.2% beat. Management raised full-year adjusted EPS guidance to $8.94. Operating margin remained steady at 21.9%, while free cash flow margin improved to 22.5%.